Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV

    loading  Checking for direct PDF access through Ovid

Abstract

We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.

Related Topics

    loading  Loading Related Articles